MedTrace Logo

A Study of miRNA 371 in Patients With Germ Cell Tumors

NCT04435756 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 956

Last updated 2026-03-12

No results posted yet for this study

Summary

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Conditions

  • Germ Cell Tumor
  • Metachronous Malignant Neoplasm
  • Seminoma
  • Stage I Testicular Cancer AJCC v8
  • Stage IA Testicular Cancer AJCC v8
  • Stage IB Testicular Cancer AJCC v8
  • Stage IS Testicular Cancer AJCC v8

Interventions

OTHER

Biomarker Analysis

Correlative study

PROCEDURE

Blood Product Collection

Undergo collection of blood

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Craig R Nichols · SWOG Cancer Research Network

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2027-01-01
Completion
2028-01-01

Countries

  • United States
  • Canada
  • Guam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435756 on ClinicalTrials.gov